| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 13.38% | 14.29% | 13.19% | 12.48% | 10.04% | 6.44% | 7.01% | 7.12% | 7.38% | 9.33% | 11.27% | 10.81% |
| EBITDA Margin | 20.39% | 21.53% | 20.70% | 20.33% | 19.15% | 17.77% | 17.85% | 18.08% | 17.76% | 13.54% | 13.50% | 13.03% |
| Net Margin | 8.34% | 8.91% | 9.06% | 7.57% | 6.96% | 2.46% | 1.72% | 2.49% | 13.44% | 1.67% | 6.75% | 6.53% |
| Current Ratio | 0.75 | 0.84 | 0.86 | 0.89 | 0.91 | 1.12 | 1.05 | 1.10 | 1.19 | 1.23 | 1.51 | 1.46 |
| Quick Ratio | 0.75 | 0.84 | 0.86 | 0.89 | 0.91 | 1.12 | 1.05 | 1.10 | 1.19 | 1.23 | 1.51 | 1.46 |
| Debt / Equity | 2.37 | 2.30 | 2.24 | 2.21 | 2.01 | 2.00 | 1.86 | 1.58 | 1.22 | 0.81 | -7.35 | -3.26 |
| ROE | 20.51% | 22.63% | 22.22% | 18.92% | 15.99% | 4.44% | 3.05% | 3.72% | 15.66% | 1.30% | -115.35% | -50.62% |
| ROA | 4.54% | 5.10% | 5.09% | 4.31% | 3.91% | 1.14% | 0.82% | 1.15% | 5.76% | 0.54% | 9.86% | 10.78% |
| Asset Turnover | 0.54 | 0.57 | 0.56 | 0.57 | 0.56 | 0.46 | 0.48 | 0.46 | 0.43 | 0.32 | 1.46 | 1.65 |
| Book Value / Share | 38.21 | 33.08 | 32.81 | 30.25 | 30.98 | 32.21 | 31.38 | 33.40 | 37.55 | 58.29 | -2.67 | -5.37 |
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company supports pharmaceutical, biotechnology, medical device, and healthcare organizations in developing, testing, and commercializing therapies using extensive real-world data, predictive analytics, and technology platforms. Its Technology and Analytics Solutions segment delivers healthcare data, decision-support tools, and software to clients such as manufacturers, providers, payers, and policymakers, helping them optimize clinical and commercial performance. The Research and Development Solutions segment focuses on outsourced clinical trial services, including late-stage and virtual clinical trials for drugs, devices, and diagnostics. IQVIA also offers contract sales and medical solutions that assist with commercialization and field-based engagement. Founded in 1950 and headquartered in Durham, North Carolina, IQVIA plays a central role in the healthcare ecosystem by enabling more efficient evidence generation, regulatory submissions, and market access strategies across more than 100 countries worldwide.